Infectivity of hepatitis C virus is influenced by association with apolipoprotein E isoforms.
Hepatitis C virus (HCV) is a causative agent of chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma. HCV in circulating blood associates with lipoproteins such as very low density lipoprotein (VLDL) and low-density lipoprotein (LDL). Although these associations suggest that lipoproteins are important for HCV infectivity, the roles of lipoproteins in HCV production and infectivity are not fully understood. To clarify the roles of lipoprotein in the HCV life cycle, we analyzed the effect of apolipoprotein E (ApoE), a component of lipoprotein, on virus production and infectivity. The production of infectious HCV was significantly reduced by the knockdown of ApoE. When an ApoE mutant that fails to be secreted into the culture medium was used, the amount of infectious HCV in the culture medium was dramatically reduced; the infectious HCV accumulated inside these cells, suggesting that infectious HCV must associate with ApoE prior to virus release. We performed rescue experiments in which ApoE isoforms were ectopically expressed in cells depleted of endogenous ApoE. The ectopic expression of the ApoE2 isoform, which has low affinity for the LDL receptor (LDLR), resulted in poor recovery of infectious HCV, whereas the expression of other isoforms, ApoE3 and ApoE4, rescued the production of infectious virus, raising it to an almost normal level. Furthermore, we found that the infectivity of HCV required both the LDLR and scavenger receptor class B, member I (SR-BI), ligands for ApoE. These findings indicate that ApoE is an essential apolipoprotein for HCV infectivity.
Hishiki
Takayuki
T
Research Institute, Chiba Institute of Technology, Narashino City, Chiba 275-0016, Japan. takayuki.hishiki@it-chiba.ac.jp
Shimizu
Yuko
Y
Tobita
Reiri
R
Sugiyama
Kazuo
K
Ogawa
Kazuya
K
Funami
Kenji
K
Ohsaki
Yuki
Y
Fujimoto
Toyoshi
T
Takaku
Hiroshi
H
Wakita
Takaji
T
Baumert
Thomas F
TF
Miyanari
Yusuke
Y
Shimotohno
Kunitada
K
D053329:Apolipoprotein E2 / Q000235:genetics / Q000378:metabolism*; D053318:Apolipoprotein E3 / Q000235:genetics / Q000378:metabolism*; D053327:Apolipoprotein E4 / Q000235:genetics / Q000378:metabolism*; D045744:Cell Line, Tumor; D016174:Hepacivirus / Q000502:physiology*; D006526:Hepatitis C / Q000235:genetics / Q000378:metabolism* / Q000821:virology; D006801:Humans; D011485:Protein Binding
D053329:Apolipoprotein E2; D053318:Apolipoprotein E3; D053327:Apolipoprotein E4
Hepatology. 2007 Dec;46(6):1722-31
18000990
Proc Natl Acad Sci U S A. 2004 Aug 31;101(35):13038-43
15326295
J Virol. 2007 Dec;81(24):13783-93
17913825
J Virol. 1993 Mar;67(3):1385-95
7679746
J Biol Chem. 2003 Oct 24;278(43):41624-30
12913001
Proc Natl Acad Sci U S A. 2007 Apr 3;104(14):5848-53
17376867
Nat Cell Biol. 2007 Sep;9(9):1089-97
17721513
Hepatology. 2010 Jan;51(1):43-53
20014138
Biochim Biophys Acta. 2000 Jan 3;1483(1):37-57
10601694
J Virol. 2008 Aug;82(16):7964-76
18524832
Gut. 2006 May;55(5):715-8
16299033
Hepatology. 2008 May;47(5):1437-45
18393287
Virology. 2010 Nov 10;407(1):152-9
20822787
PLoS Pathog. 2008 Mar 21;4(3):e1000032
18369478
Mol Biosyst. 2007 Sep;3(9):608-19
17700861
J Virol. 2006 Mar;80(5):2418-28
16474148
J Virol. 2009 Jul;83(13):6922-8
19369330
J Virol. 2009 Dec;83(24):12680-91
19793818
Annu Rev Genomics Hum Genet. 2000;1:507-37
11701639
J Virol. 2002 Jul;76(14):6919-28
12072493
Proc Natl Acad Sci U S A. 2006 Mar 7;103(10):3805-9
16484368
Virology. 2009 Nov 10;394(1):99-108
19751943
J Virol. 2008 Mar;82(5):2120-9
18077707
J Biol Chem. 2002 Jun 14;277(24):21149-57
11861652
PLoS Pathog. 2008 Mar 28;4(3):e1000035
18369481
Hepatology. 2010 Apr;51(4):1144-57
20069648
J Gen Virol. 2006 Oct;87(Pt 10):2983-2991
16963757
J Virol. 2008 Oct;82(19):9647-56
18667498
Nat Med. 2005 Jul;11(7):791-6
15951748
Hepatology. 1993 Dec;18(6):1326-33
8244256
J Virol. 2000 Nov;74(21):10055-62
11024134
J Virol. 1993 Aug;67(8):4665-75
8392606
Arteriosclerosis. 1988 Jan-Feb;8(1):1-21
3277611
J Hepatol. 2007 Mar;46(3):411-9
17156886